RxDoctor Payments Data

Diana McFarlane, PA

Medical · Seattle, WANPI 1336113885

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Enterra Medical, Inc. accounts for 91.4% of it on its own, with 6 other manufacturers making up the rest. Among medical clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$94,982in general payments, 2019–2025

Across 120 payments — averaging $791.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Enterra Medical, Inc.$87K
  • Ardelyx, Inc.$8K
  • Regeneron Healthcare Solutions, Inc.$150
  • Medtronic$125
  • Ferring Pharmaceuticals Inc.$78
  • AbbVie$44
  • plus $34 from 1 others

What the payments were for

  • Consulting fees$31,75033%
  • Speaking & faculty fees$46,93849%
  • Travel & lodging$9,93310%
  • Food & beverage$6,3627%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,982 in reported general payments places this provider in the 95th percentile of 457 medical providers in Washington.

See all medical providers in Washington

Medicare billing

Part B allowed, 2024
$61,596
Medicare patients
219
Services billed
1,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase57$151,219
Humira(Cf) PenAdalimumab14$97,412
LinzessLinaclotide112$92,836
XifaxanRifaximin24$54,142
MotegrityPrucalopride Succinate29$19,754
Aprepitant33$17,562
Sucralfate11$5,882
Scopolamine44$5,055
Dexlansoprazole DrDexlansoprazole13$3,613
CholestyramineCholestyramine (With Sugar)35$3,411
Colestipol Hcl29$2,894
Promethazine Hcl81$2,480
Omeprazole114$2,002
Lubiprostone25$1,849
Ondansetron OdtOndansetron94$1,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$44$244,055169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 medical providers in Washington.

Other medical in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →